



#7 #1

CERTIFICATE OF MAILING (37 C.F.R. §1.8 (a))

I hereby certify that the attached papers or fee are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

8/13/02

(Date)

Angela L. Kratky

(Printed Name)

(Signature)

DOCKET NO.: 70332-4/US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Ghildyal *et al.***

Application No.: **10/040,884**

Group Art Unit: **1646**

Filed: **January 7, 2002**

Examiner: **Not yet assigned**

For: **Human Receptor Tyrosine Kinase**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicants submit herewith a list of patents and publications which Applicants believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. §1.56.


Some of the references (marked with an asterisk) listed on the attached Form PTO-1449 were submitted to the Patent and Trademark Office during the prosecution of prior filed U.S. Application Number 09/310,438, which application is relied upon for an earlier filing date under 35

DOCKET NO.: 70332-4/US
PATENT APPLICATION

SERIAL NO.: 10/040,884
FILED: JANUARY 7, 2002


This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Respectfully submitted,



Robin S. Quartin, Ph.D.
Registration No. **45,028**
(302) 885-9129

Date: *August 13, 2002*



Form PTO-1249

INFORMATION DISCLOSURE CITATION BY APPLICANT

(Use s v r a l s h e t s i f n e c e s s a r y)

DOCKET NUMBER
70332-4/US

APPLICATION NUMBER
10/040,884

APPLICANT
Ghildyal *et al.*

FILING DATE
January 7, 2002

GROUP ART UNIT
1646

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	* 5,763,584	06-09-1998	Godowski	530	402	
	* 5,763,470	06-09-1998	Tang <i>et al.</i>	514	406	
	* 5,763,198	06-09-1998	Hirth <i>et al.</i>	435	7.21	
	* 5,763,441	06-09-1998	App <i>et al.</i>	514	249	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 97/34920	09-25-1997	PCT				
	WO 95/30331	11-16-1995	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	* Shawver <i>et al.</i> , 1997, Receptor tyrosine kinases as targets for inhibition of angiogenesis, Drug Discovery Today, 2:50-63.
	* Herz <i>et al.</i> , 1997, Molecular approaches to receptors as targets for drug discovery, J. Recept. Signal Transduct. Res., 17:671-776 .
	Marra <i>et al.</i> , The WashU-HHMI mouse EST project, EMBL ACC NO AA098024, 27 October 1996.
	Auffray <i>et al.</i> , IMAGE: integrated molecular analysis of the human genome and its expression, EMBL ACC NO Z42722, 6 November 1994.
	Rubin Grandis <i>et al.</i> , Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells, Oncogene, 15:409-416.

* COPIES PREVIOUSLY SUBMITTED WITH THE PATENT APPLICATION, SERIAL NO. 09/310,438.

Form PTO-1449 INFORMATION DISCLOSURE CITATION BY APPLICANT <i>(Use several sheets if necessary)</i>	DOCKET NUMBER 70332-4/US	APPLICATION NUMBER 10/040,884
	APPLICANT Ghildyal <i>et al.</i>	
	FILING DATE January 7, 2002	GROUP ART UNIT 1646

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Chou <i>et al.</i> , 1987, Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin, J. Bio. Chem., 262:1842-1847.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	